KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Tuesday
Sep082015

NCT02545868

This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Condition: Multiple Sclerosis, Relapsing-Remitting
Sponsor: Hoffman-LaRoche
Phase 3 
Tuesday
Aug252015

NCT02543749

DC Vaccination in CML

Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia

Condition: Chronic Myeloid Leukemia
Sponsor: Charite University, Berlin, Germany
Phase 1
Phase 2  

Friday
Jul242015

NCT02508896

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (AFF012)

A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE® Vaccines in Healthy Subjects

Condition: Hypercholesterolemia
Sponsor: Affiris AG
Collaborator: Medical University of Vienna
Phase 1
 

Friday
May222015

NCT02455557

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Condition: Glioblastoma
Sponsor: Roswell Park Cancer Institute
Collaborator: National Cancer Institute (NCI) 
Phase 2 

Tuesday
Jan062015

NCT02334735

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Conditions: Melanoma
Sponsor: Nina Bhardwaj
Collaborators: New York University School of Medicine, Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, Melanoma Research Alliance, Oncovir Inc.
Phase 2

Tuesday
Jan062015

NCT02334865

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Conditions: Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
Sponsor: Roswell Park Cancer Institute
Collaborator: National Cancer Institute (NCI) 
Phase 1

Tuesday
Jan062015

NCT02334735

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Condition: Melanoma
Sponsor: Nina Bhardwaj
Collaborators: New York Univ School of Medicine, MEmorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, Melanoma Research Alliance, Oncovir, Inc. 

Thursday
Sep042014

NCT02270489

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA (AFF009)

A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System Atrophy

Conditions: Multiple System Atrophy, Neurodegenerative Diseases
Sponsor: Affiris AG
Collaborators: 
University Hospital, Bordeaux; Institut National de la Santé Et de la Recherche Médicale, France; Forschungszentrum Juelich; University Hospital, Toulouse
Phase 1 

 

 

Thursday
Sep042014

NCT02267434

Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease (AFF011)

A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease

Condition:  Parkinson's Disease
Sponsor: AFFiRis
Collaborators:  PROSENEX Ambulatoriumbetriebs GMBH, Medical University Innsbruck, Forschungszentrum Juelich
Phase 1

 

Tuesday
May062014

NCT02132988

Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Ovarian Cancer
Sponsor: Mackay Memorial Hospital
Collaborator: OBI Pharma, Inc.
Phase II